4/22
09:11 am
pstv
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense [Yahoo! Finance]
Neutral
Report
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense [Yahoo! Finance]
4/22
07:15 am
pstv
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense [Yahoo! Finance]
Low
Report
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense [Yahoo! Finance]
4/22
07:00 am
pstv
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
High
Report
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
4/9
07:00 am
pstv
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
Medium
Report
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
3/27
08:00 am
pstv
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
Medium
Report
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
3/25
08:06 am
pstv
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic [Yahoo! Finance]
Medium
Report
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic [Yahoo! Finance]
3/25
08:00 am
pstv
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
Low
Report
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
3/11
07:35 am
pstv
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases [Yahoo! Finance]
Medium
Report
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases [Yahoo! Finance]
3/11
07:00 am
pstv
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
Medium
Report
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
3/7
09:16 am
pstv
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
06:37 am
pstv
Plus Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Plus Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
3/5
04:08 pm
pstv
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
High
Report
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
3/5
04:05 pm
pstv
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
High
Report
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
2/27
08:00 am
pstv
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
Medium
Report
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024